- 1 HIV VIRAL SUPPRESSION AND ASSOCIATED FACTORS AMONG
- 2 CHILDREN AND ADOLESCENTS ON A DOLUTEGRAVIR (DTG) BASED
- 3 ANTIRETROVIRAL REGIMEN IN TANZANIA MAINLAND
- 5 Abdallah Abtwalibe Maghembe^{1§}, Marion Sumari-de Boer^{1 2 3}, Godbless Marikias⁴, Caroline
- 6 Amour¹², Michael Johnson Mahande¹²
- 7 Affiliations

14

17

18

- 8 ¹Institute of Public Health, Department of Epidemiology and Biostatistics, Kilimanjaro
- 9 Christian Medical University College (KCMUCo), Moshi, Tanzania.
- ²Institute of Public Health, Department of Community Medicine, Kilimanjaro
- 11 Christian Medical University College (KCMUCo), P. O. Box 2240, Moshi, Tanzania
- ³Amsterdam Institute of Global Health and Development, Amsterdam, the Netherlands
- ⁴Management and Development of Health (MDH), Dar es Salaam, Tanzania
- 15 § Corresponding author: Abdallah Abtwalibe Maghembe, KCMUCo, P. O. Box 2240, Moshi,
- Tanzania, Phone number: +255763724375 E-mail: abdallahmaghembe@gmail.com

- 19 **Keywords:** Dolutegravir (DTG), HIV/AIDS, viral suppression, Integrase Strand Transfer
- 20 Inhibitor, associated risk factors, children and adolescents living with HIV (CALHIV).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

clubs and teams.

53

21

Introduction: Antiretroviral therapy (ART) reduces morbidity and mortality due to human 22 immunodeficiency virus (HIV) infection. The complexity and time-consuming processes, 23 particularly in drug approvals, have contributed to a major challenge to the ongoing success of 24 antiretroviral treatment programs among children and adolescents. In 2019, Tanzania adopted 25 DTG as a first-, second-line and third-line treatment for CALHIV on ART after being approved 26 by the World Health Organisation (WHO). DTG treatment has highly potent antiviral activity, 27 a high genetic barrier to resistance, and a high safety profile. This study aimed to determine 28 HIV viral suppression and associated factors among CALHIV on DTG-based ART in Tanzania 29 30 Mainland. **Methods:** This was a retrospective cohort analysis among children and adolescents living with 31 HIV who were on a DTG-based regimen in Tanzania Mainland between 2019 and 2021. The 32 study utilized routinely collected data from Tanzania Care and Treatment Centres (CTC). We 33 analysed data using STATA version 15 software. We calculated the prevalence of viral 34 suppression by taking the number of children and adolescents with <1000 copies/ml overall 35 study participants. A mixed effect generalized linear model with Poisson distribution and log 36 link function with robust estimator determined the factors associated with HIV viral 37 suppression on a DTG-based regimen. 38 **Results:** A total of 63,453 CALHIV on a DTG-based regimen were analysed. The proportion 39 of viral suppression was 91.64%. Overall, 66.19% of previously unsuppressed individuals 40 became suppressed and 88.45% of previously suppressed remained suppressed. Factors leading 41 to lower chances of viral suppression were age 10-14 years (aRR: 0.98; 95%CI: 0.97-0.99), 42 previously unsuppressed prior to starting DTG (aRR: 0.92; 95%CI: 0.91-0.93), duration on 43 ART more than 24 months (aRR: 0.96; 95%CI: 0.94-0.97), not retained in care (aRR: 0.83; 44 95% CI: 0.77-0.89), severe malnutrition (aRR:0.77; 95%CI: 0.69-0.94) and coastal zone (aRR: 45 0.98; 95% CI: 0.96-0.99), while those in WHO stage I (aRR: 1.03; 95%CI: 1.01-1.04) and ever 46 received a multi-month prescription (aRR: 1.25; 95% CI: 1.23-1.28) had a higher chance of 47 viral suppression. 48 49 Conclusions: The findings support the broad use of DTG-based regimens for eligible CALHIV. Especially those in baseline WHO stage I and those who received the multi-month 50 prescriptions were more likely to achieve viral load suppression. Programs should improve 51 strategies to maintain CALHIV retention in care with interventions like the promotion of teen 52

Introduction

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

HIV/AIDS is one of the greatest public health challenges in the world, whereby sub-Saharan Africa remains the region most heavily affected in the world. An estimated 1.8 (1.2-2.2) million children aged 0-14 were living with HIV at the end of 2020, and 150,000 children were newly infected. An estimated 100,000 children died of AIDS-related illnesses [1]. In Tanzania, it is estimated that around 110,000 (93,000 – 130,000) children aged 0-14 years and 1.6 (1.5 - 1.8) million adults were living with HIV/AIDS in 2020 [2]. From the Tanzania 2020 estimates, there were 6,500 new infections among children below 15 years of aged and 78% of children living with HIV are on ART [2]. The prevalence of HIV according to the THIS of 2016/2017 was less than 2% among 15-19 years for both males and females and increases with age for both sexes. HIV care and treatment programs have scaled up rapidly in many countries in sub-Saharan Africa in recent years. The National AIDS Control Programme (NACP) in Tanzania has been coordinating the scale-up of quality HIV care and treatment services at all health facility levels: including public and private hospitals and in health centres and dispensaries throughout the country, whereby 6,206 (2103 CTCs & 4103 Option B+) health facilities started to provide care and treatment by December 2018 [3]. In Tanzania, according to the Fourth Health Sector HIV and AIDS Strategic Plan (HSHSP IV) strategic outcomes, all children living with HIV under 15 years should be initiated ART and 90% of children should be retained on ART by 2022 as well as 95% of adolescents living with HIV should be retained on ART by 2022 [4]. Viral suppression is a good long-term outcome for survival and maturing to the ongoing success of antiretroviral treatment programs in limited resources countries among children living with HIV [5]. To meet the United Nations AIDS (UNAIDS) goals the agreement is to eliminate HIV by 2030 with the recommended 95-95-95 targets (diagnosis of 95% of HIV-infected people, provision

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

of treatment for 95% of people diagnosed with HIV, and viral un-detectability in 95% of treated people). The complexity of the treatment regime among children and adolescents is still a big challenge for HIV programs in sub-Saharan Africa and forms an obstacle to the attainment of the second and third targets of the UNAIDS 95-95-95 HIV treatment targets among children and adolescents as it affects sustainable treatment and virological success of children and adolescents living with HIV accessing care and treatment service [6]. Major improvements in access to treatment have been greater for adults than for children due to the fundamental challenge in the development and approval of paediatric dosing and formulations for age and weight-specific thresholds for children and adolescents lagging behind for years and children did not benefit compared to adults despite the same level of engagement in terms of ART uptake [7]. Dolutegravir (DTG) is an Integrase Strand Transfer Inhibitor (INSTI) used as a first-line, second-line, and third-line HIV treatment regimen. According to the World health organization (WHO) updated antiretroviral therapy guidelines of 2018, Dolutegravir (DTG) is recommended at ≥6 years of age or weight ≥20 kg, and children weight for age below <20 kg use Lopinavir/ritonavir with or without being exposed to the Nevirapine among exposed infants from the risk mothers. Tanzania adopted DTG in 2019 among children and adolescents weighing ≥20kg. Hence, there is a need to study treatment outcomes of DTG-based ART regimens due to its potent antiviral activity in reducing the HIV incidence by promoting rapid viral suppression, a high genetic barrier to resistance and better safety profile [8]. Yet, in our setting, the prediction of viral suppression and associated factors has not been validated. Thus, there is still little support for the use of DTG-based regimens in mass treatment programs. Hence, there is need to assess viral suppression among children and adolescents that are on these new antiretroviral drugs. This is because a single study on DTG has shown adolescents

- born in Sub-Saharan countries were more likely to have virological failure compared to those
- born in other countries [9].

Methods

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

Study design and setting This was a retrospective cohort study among children and adolescents living with HIV who were on an ART-initiated DTG based regimen in Tanzania Mainland between January 2019 and December 2021. The study utilized routinely collected data of Tanzania Care and Treatment Centres (CTC). Study population and Period The analysis includes children and adolescents living with HIV (CALHIV) on a dolutegravirbased regimen, who were aged 1 year to 19 years in care and treatment clinics (CTCs) in Tanzania Mainland between January 2019 and December 2021. We excluded all HIV-positive children and adolescents with less than six (6) months on ART accessing care and treatment, and missing viral load result after initiation of DTG from the study. Sample size estimation A total of 230,310 Children and Adolescents Living with HIV (CALHIV) patients in Tanzania mainland enrolled from January 2019 and December 2021. A total of 96,648 (41.96%) of CALHIV were on a dolutegravir (DTG) based regimen and 133,662 (58.04%) were on NNRTI and PI. We excluded a total of 33,195 (33.01%) individuals on DTG from the analysis as they did not meet eligibility criteria. The final sample was 63,453 as shown in our flow diagram (Figure 1). Data sources and study variables This study utilized data of HIV-positive children and adolescent's clients that were on DTG from January 2019 to December 2021. We obtained data from routinely collected data of the care and treatment clinics (CTC) for HIV-positive clients in Tanzania. We only included health

facilities who initiated DTG-based regimens. The data set originates from the National Aids Control Programme (NACP).

We defined the dependent variable, HIV viral suppression, as having a last plasma viral load of less than <1000 copies/ml, which we named "Yes" 1 and having a plasma viral load of equal and greater than 1000 copies/ml we named "No" 0.

Independent variables were age in the following categories: sex, WHO clinical stages (Stage I, II, III and IV), CD4 cell count (<200, 200-350 and >350), BMI categorized as underweight (<18.5kg/m²), normal weight (18.5-24.9 kg/m²), overweight (25-29.9 kg/m²) and obese (≥30 kg/m²), prior DTG status (Experienced suppressed, experienced unsuppressed and Naive), duration on ART (6-12 months, 13-24 months and >24 months), ever received Multi Month Subscription (Yes and No), history of TB treatment (Yes and No), retention in care (In care, lost to follow up, transferred and died) and geographical zones (central, lake, western, northern, coastal and southern highland).

Data Analysis

We analysed data using STATA version 15.0 software (Stata Corp, 2017. Stata Statistical Software: Release 15 College Station, USA). We conducted descriptive statistics for all variables; we summarized continuous variables using mean (SD) or median (IQR), depending on their distribution, and frequency and proportion for categorical variables. We computed a proportion of HIV viral suppression as the number of children and adolescents with <1000 copies/ml over all study participants. We did Chi-square tests for each explanatory variable to compare the proportion of HIV viral suppression on DTG based regimen. We used a multilevel mixed effects Generalized Linear Model with a Poisson distribution and log link function with a robust estimator to determine the association between exposures and HIV viral suppression on DTG based regimen. We interpreted the magnitude of association using an adjusted relative risk and 95% CI, while a p-value of less than 0.05 was statistically significant. We included

those variables identified based on prior and clinical knowledge of the study setting in the adjusted model.




Figure 1: Flow chart showing the recruitment of the study population.

Ethical clearance

Ethical approval with clearance number PG 12/2021 to conduct the study was obtained from KCMU College and Research Ethics Review Committee. The study utilized secondary data from routinely collected data of the care and treatment clinics (CTC) for HIV-positive clients in Tanzania hence the permission to carry out the study was obtained from National AIDS Control Programme (NACP) to access patient level information in the CTC 2 Databases. The obtained information was kept confidential and participant codes from CTC identity numbers were used instead of names.

Results

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

Proportion of CALHIV on DTG-based ART A total of 96,648 CALHIV were on a DTG based regimen from January 2019 to December 2021, representing 41.96% of all CALHIV on ART regimens. Among the DTG cohort, 17,925 (18.56%) were new ART initiations started on DTG (Naive), 52,275 (54.07%) were switched from an NNRTI and 26,448 (27.37%) were switched from a PI regimen. Socio-demographic and clinical characteristics among the CALHIV We studied a total of 63,453 children and adolescents living with HIV on DTG based regimen. Findings showed that the majority of CALHIV, 21,852 (34.44%), were aged 1-4 years and the mean age was 7.74 (SD: 5.37) years at baseline. Most study participants (36,108 (56.91%)) were females. At baseline, many of the study participants were experienced suppressed with 34,557 (63.37%) prior to starting DTG, 13,041 (23.91%) were experienced unsuppressed prior to starting DTG and 6,933 (12.71%) were naïve prior to starting DTG. Most of the study participants 53,512 (84.33%) had more than 24 months duration on antiretroviral therapy. With reference to study participants, 26,977 (42.73%) were attending hospital facility type, 48,070 (76.14%) were attending a public facility and 17,152 (27.17%) were living in the lake zone. More results are shown in **Table 1**.

Table 1: Socio-demographic and clinical characteristics in Children and Adolescent Living with HIV (CALHIV) (N=63,453)

Variables	Frequency (n)	Percentage (%)
Sex	1 / (/	
Male	27,345	43.09
Female	36,108	56.91
Age (years)	,	
1-4	21,852	34.44
5-9	20,009	31.53
10-14	11,707	18.45
15-19	9,885	15.58
Mean Age in Years (SD)	7.74 (5.37)	
Base WHO Clinical Staging		
Stage I	26,026	41.02
Stage II	18,026	29.54
Stage III	16,112	25.40
Stage IV	2,565	4.04
Baseline CD4 cells/mm ³ (n=35,478)		
<200	3,101	8.74
200-349	1,905	5.37
>=350	30,472	85.89
Median CD4 cell count (IQR)	427 (162-742)	
Baseline BMI (Kg/M²) (n=23,687)		
Underweight	18,478	78.01
Normal	3,312	13.98
Overweight	510	2.15
Obesity	1,387	5.86
Median BMI (IQR)	15.6 (13.9-17.9)	
Prior DTG status (n=54,531)		
Experienced Suppressed	34,557	63.37
Experienced Unsuppressed	13,041	23.91
Naive	6,933	12.71
Duration on ART		
6-12 months	3,833	6.04
13-24 months	6,108	9.63
>24 months	53,512	84.33
DTG Regimen (n=63,303)	20.645	61.05
TDF+3TC+DTG (TLD)	38,645	61.05
ABC+3TC+DTG	22,578	35.67
AZT+3TC+DTG	2,080	3.29
Ever Received MMS	7.476	11.70
No	7,476	11.78
Yes Child exposed to PMTCT	55,977	88.22
No	50 217	01.75
Yes	58,217 5.236	91.75 8.25
History of TB treatment	5,236	0.43
No	57,592	90.76
Yes	5,861	90.76
105	3,001	9.4 4

Current Malnutrition Status		
(n=56,083)		
No Malnutrition	55,601	99.14
Mild & Moderate	450	0.80
Severe	32	0.06
Regimen		
First line	56,870	89.62
Second line	6,583	10.38
Retention in Care		
In care	63,047	99.36
Lost to Follow up	24	0.04
Transferred	65	0.10
Died	317	0.50
Facility type (n=63,136)		
Dispensary	15,494	24.54
Health centre	20,665	32.73
Hospital	26,977	42.73
Facility Ownership (n=63,136)		
Private/FBO	15,066	23.86
Public	48,070	76.14
Zone (n=63,136)		
Central Zone	6,510	10.31
Coastal Zone	13,400	21.22
Lake Zone	17,152	27.17
Northern Zone	7,536	11.94
Southern Highland	16,907	26.78
Western Zone	1,631	2.58

Frequency (n) do not tally to the total due to missing values

Abbreviation: MMS, Multi-month Subscription; PMTCT, Prevention of Mother to Child Transmission; TB, Tuberculosis; BMI, Body Mass Index; CD4, Cluster of differentiation 4; ART, Antiretroviral Therapy; FBO, Faith based organizations; DTG, dolutegravir; TDF, tenofovir; 3TC, lamivudine; ABC, abacavir; AZT, azidothymidine (Zidovudine); ART, Antiretroviral Therapy

Proportion of HIV viral suppression among children and adolescents on Dolutegravir

(DTG) based ART

183

184

185

186

187

188

189

190

Among CALHIV on a DTG-based regimen with pre- and post-viral load tests, 88.4% of those who were suppressed before DTG, remained suppressed. Of those who were unsuppressed before DTG, 66.1% became suppressed. After six months on DTG, among naïve patients on DTG based regimen, 91.7% achieved viral suppression as shown in **Figure 2**.




Figure 2: Viral Suppression at baseline, after 6 months among Naïve and last viral load among CALHIV on DTG-based regimen (N=54,531)

In addition, the proportion of CALHIV on a DTG-based regimen who achieved viral suppression was higher in ART naïve (93.2%) than in treatment-experienced CALHIV with (91.4%) p-value <0.001, as shown in **Figure 3**.




Figure 3: Viral Load among treatment naïve and experienced CALHIV on DTG-based regimen (N=63,453) p-value <0.001.

Among the 63,453 children and adolescents living with HIV on DTG, the prevalence of viral suppression was 91.64% (95%CI: 91.42-91.85; N=58,147). The proportion of viral suppression among females was significantly higher with 92.04% (95%CI: 91.76,92.32) compared to viral suppression among males with 91.10% (95%CI: 90.76,91.43).

Among those with pre- and post-DTG VL, 94.28% (95%CI: 94.04,94.52) of previously suppressed participants remained suppressed, 84.85% (95%CI: 84.22,85.45) of previously unsuppressed became virally suppressed and 93.21% (95%CI: 92.59,93.78) of treatment-naïve participants who started DTG became viral suppressed. Among CALHIV on a DTG-based regimen with 24 months or less duration on ART had a significantly higher proportion of viral suppression with 92.72% (95%CI: 92.19,93.21) compared to individuals with a duration of more than two years (12 months) on ART with 91.44% (95% CI: 91.20,91.67). More results are shown in **Table 2**.

Table 2: Proportion of HIV viral suppression by Socio-demographic and Clinical Characteristics of the CALHIV on DTG based ART (N=63,453)

	Viral Load			
Variables	Unsuppressed Suppressed (<1000 copies/ml		00 copies/ml)	– – P-value
variables	n (%)	n (%)	95% CI	r-value
	5,306 (8.36%)	58,147 (91.64%)	91.42,91.85	
Sex				< 0.001
Male	2,433 (8.90)	24,912 (91.10)	90.76,91.43	
Female	2,873 (7.96)	33,235 (92.04)	91.76,92.32	
Age (years)				< 0.001
1-4	1,684 (7.71)	20,168 (92.29)	91.93,92.64	
5-9	1,810 (9.05)	18,199 (90.95)	90.55,91.34	
10-14	1,123 (9.59)	10,584 (90.41)	89.86,90.93	
15-19	689 (6.97)	9,196 (93.03)	92.51,93.52	
WHO Staging	,		ŕ	< 0.001
Stage I	2,015 (7.74)	24,011 (92.26)	91.93,92.58	
Stage II	1,585 (8.46)	17,156 (91.54)	91.14,91.93	
Stage III	1,449 (8.99)	14,663 (91.01)	90.56,91.44	
Stage IV	254 (9.90)	2,311 (90.10)	88.88,91.20	
CD4 (cells/mm3)	()	, ()	,	0.008
<200	298 (9.61)	2,803 (90.39)	89.30,91.38	
200-349	175 (9.19)	1,730 (90.81)	89.43,92.03	
>=350	2,487 (8.16)	27,985 (91.84)	91.53,92.03	
BMI (Kg/M ²)	2,407 (0.10)	27,703 (71.04)	71.33,72.03	0.512
Underweight	1,610 (8.71)	16,868 (91.29)	90.87,91.69	0.312
Normal	262 (7.91)	3,050 (92.09)	91.12,92.96	
Overweight	44 (8.63)	466 (91.37)	88.60,93.52	
Obesity	` /	` /		
Prior DTG status	119 (8.58)	1,268 (91.42)	89.83,92.78	<0.001
	1 075 (5 72)	22 592 (04 29)	04.04.04.53	< 0.001
Experienced Suppressed	1,975 (5.72)	32,582 (94.28)	94.04,94.52	
Experienced Unsuppressed	1,976 (15.15)	11,065 (84.85)	84.22,85.45	
Naive	471 (6.79)	6,462 (93.21)	92.59,93.78	<0.001
Duration on ART	724 (7.20)	0.217 (02.72)	02 10 02 21	< 0.001
24 months or less	724 (7.28)	9,217 (92.72)	92.19,93.21	
>24 months	4,582 (8.56)	48,930 (91.44)	91.20,91.67	0.202
Current DTG Regimen	100 (= 01)	1 202 (02 (0)	04.00.04	0.382
Other DTG regimen	109 (7.31)	1,383 (92.69)	91.26,93.81	
TDF+3TC+DTG (TLD)	389 (6.67)	5,445 (93.33)	92.66,93.94	
Ever Received MMS				< 0.001
No	1,785 (23.88)	5,691 (76.12)	75.14,77.08	
Yes	3,521 (6.29)	52,456 (93.71)	93.51,93.91	
Child exposed to PMTCT				0.147
No	4,896 (8.41)	53,321 (91.59)	91.36,91.81	
Yes	410 (7.83)	4,826 (92.17)	91.41,92.87	
History of TB treatment				0.001
No	4,749 (8.25)	952,843 (91.75)	91.53,91.98	
Yes	557 (9.50)	5,304 (90.50)	89.72,91.22	

Malnutrition Status				< 0.001
No Malnutrition	4,671 (8.40)	50,930 (91.60)	91.37,91.83	
Mild & Moderate	49 (10.89)	401 (89.11)	85.88,91.68	
Severe	10 (31.25)	22 (68.75)	50.72,82.46	
Retention in Care		, ,		< 0.001
Retained	5,183 (8.22)	57,864 (91.78)	91.56,91.99	
Not Retained	123 (30.30)	283 (69.70)	65.05,73.99	
Facility type		, ,		0.021
Dispensary	1,365 (8.81)	14,129 (91.19)	90.73,91.63	
Health centre	1,751 (8.47)	18,914 (91.53)	91.14,91.90	
Hospital	2,172 (8.05)	24,805 (91.95)	91.62,92.27	
Facility Ownership				0.240
Private/FBO	1,227 (8.14)	13,839 (91.86)	91.41,92.28	
Public	4,061 (8.45)	44,009 (91.55)	91.30,91.79	
Zone				< 0.001
Central Zone	502 (7.71)	6,008 (92.29)	91.62,92.91	
Coastal Zone	1,352 (10.09)	12,048 (89.91)	89.39,90.41	
Lake Zone	1,023 (5.96)	16,129 (94.04)	93.67,94.38	
Northern Zone	657 (8.72)	6,879 (91.28)	90.62,91.90	
Southern Highland	1,618 (9.57)	15,289 (90.43)	89.98,90.86	
Western Zone	136 (8.34)	1,495 (91.66)	90.22,92.91	

Data are presented as n (row%). Abbreviations: CI, Confidence Interval; n, frequency; %, percentage; DTG, dolutegravir; TDF, tenofovir; 3TC, lamivudine; ABC, abacavir; AZT, azidothymidine (Zidovudine); MMS, Multi-month subscription; FBO, Faith based organizations; ART, Antiretroviral Therapy *Chi-squared P-value

Factors associated with viral suppression among CALHIV on DTG-based ART

Findings from crude analysis: Females are 1.01 more likely to achieve viral suppression compared to males (cRR: 1.01; 95% CI: 1.01-1.02). Participants who were ART naïve when starting a DTG based regimen are 1.01 more likely to achieve viral suppression compared to participants previously suppressed prior to DTG (cRR: 1.01; 95% CI: 1.00-1.02). Participants who ever received a multi-month subscription are 1.23 more likely to achieve viral suppression compared to participants who never received a multi-month prescription (cRR: 1.23; 95% CI: 1.23-1.25). More results are shown in **Table 3**.

Finding from multivariable regression: Participants aged 10-14 years and 5-9 years were 2% less likely to achieve viral suppression compared to participants aged 1-4 years (aRR: 0.98; 95%CI: 0.97-0.99. Also, Individuals in WHO Stage I were 1.03 more likely to achieve viral

suppression compared to individuals in WHO stage IV (aRR: 1.03; 95%CI: 1.01-1.04). Participants previously unsuppressed prior to DTG were 8% less likely to achieve viral suppression compared to participants previously suppressed (aRR: 0.92; 95%CI: 0.91-0.93). Participants with a duration on ART of more than 24 months were 4% less likely to achieve viral suppression compared to participants with a duration of 24 months or less (aRR: 0.96; 95%CI: 0.94-0.97). Participants who ever received a multi-month subscription are 1.25 more likely to achieve viral suppression compared to participants who never received a multi-month subscription (aRR: 1.25; 95% CI: 1.23-1.28). Also, those participants not retained in care were 17% less likely to achieve viral suppression compared to participants retained in care (aRR: 0.83; 95% CI: 0.77-0.89). Participants with severe nutritional status were 23% less likely to be HIV virally suppressed compared to participants with no malnutritional nutritional status (aRR:0.77; 95%CI: 0.69-0.94). However, participants living in the coastal zone were 2% less likely to achieve viral suppression compared to the participants living in the western zone (aRR: 0.98; 95% CI: 0.96-0.99). More results are shown in Table 3.

Table 3: Factors associated with viral suppression among CALHIV on DTG-based ART adjusting for clustering effect (N=63,453)

Variable	Crude Analysis		Adjusted Analysis		
	RR (95%CI)	P-value	RR (95% CI)	P-value	
Sex					
Male	1.00		1.00		
Female	1.01 (1.01-1.02)	< 0.001	1.01 (0.99-1.01)	0.095	
Age (years)					
1-4	1.00		1.00		
5-9	0.98 (0.98-0.99)	< 0.001	0.99 (0.98-0.99)	< 0.001	
10-14	0.98 (0.97-0.99)	< 0.001	0.98 (0.97-0.99)	< 0.001	
15-19	1.01 (1.00-1.02)	0.021	1.02 (1.01-1.03)	0.001	
WHO Clinical					
Stage I	1.02 (1.01-1.04)	< 0.001	1.03 (1.01-1.04)	0.003	
Stage II	1.02 (1.00-1.03)	0.016	1.02 (1.00-1.04)	0.015	
Stage III	1.01 (0.99-1.02)	0.118	1.02 (0.99-1.03)	0.062	
Stage IV	1.00		1.00		
CD4 cells/mm ³					
<200	1.00				
200-349	1.01 (0.99-1.03)	0.622			
>=350	1.02 (1.00-1.03)	0.008			
BMI (Kg/M^2)					
Underweight	1.00				
Normal	1.01 (0.99-1.01)	0.128			
Overweight	1.00 (0.958-1.03)	0.935			
Obesity	1.00 (0.99-1.02)	0.853			
Prior DTG status					
Experienced Suppressed	1.00		1.00		
Experienced Unsuppressed	0.91 (0.90-0.92)	< 0.001	0.92 (0.91-0.93)	< 0.001	
Naive	1.01 (1.00-1.02)	0.003	0.99 (0.98-1.01)	0.497	
Duration on ART					
24 months or less	1.00		1.00		
>24 months	0.98 (0.97-0.99)	< 0.001	0.96 (0.94-0.97)	< 0.001	
Current DTG Regimen	, , , , , , , , , , , , , , , , , , ,		, ,		
Other DTG regimen	1.00				
TDF+3TC+DTG(TLD)	1.01 (0.99-1.02)	0.356			
Ever received MMS					
No	1.00		1.00		
Yes	1.23 (1.21-1.25)	< 0.001	1.25 (1.23-1.28)	< 0.001	
Exposed to PMTCT	, , , , , , , , , , , , , , , , , , ,		, ,		
Ño	1.00				
Yes	1.01 (0.99-1.01)	0.120			
History of TB treatment	, , , , , , , , , , , , , , , , , , ,				
No	1.00		1.00		
Yes	0.99 (0.98-0.99)	0.003	0.99 (0.98-1.01)	0.355	
Malnutrition status	,		,		
No Malnutrition	1.00		1.00		
Mild & Moderate	0.97 (0.94-1.01)	0.129	0.98 (0.95-1.02)	0.298	
Severe	0.75 (0.63-0.89)	0.001	0.77 (0.69-0.94)	0.012	
	` '				

Retention in Care				
Retained	1.00	< 0.001	1.00	
Not Retained	0.76 (0.71-0.81)		0.83 (0.77-0.89)	< 0.001
Facility type				
Dispensary	1.00		1.00	
Health centre	1.00 (0.99-1.01)	0.365	1.00 (0.99-1.01)	0.930
Hospital	1.01 (1.00-1.02)	0.029	1.01 (0.99-1.01)	0.060
Facility Ownership				
Private/FBO	1.00			
Public	0.99 (0.99-1.01)	0.364		
Zone				
Central Zone	1.01 (0.99-1.02)	0.415	1.00 (0.98-1.02)	0.860
Coastal Zone	0.98 (0.97-0.99)	0.020	0.98 (0.96-0.99)	0.033
Lake Zone	1.03 (1.01-1.04)	0.001	1.01 (0.99-1.03)	0.227
Northern Zone	1.00 (0.98-1.01)	0.639	0.99 (0.98-1.02)	0.815
Southern Highland	0.99 (0.97-1.00)	0.102	0.99 (0.97-1.01)	0.437
Western Zone	1.00		1.00	

Key: RR; Relative Risk CI; Confidence Interval

242

243

Discussion

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

This study aimed to determine HIV viral suppression and associated factors among children and adolescents who were on a DTG-based regimen in Tanzania Mainland from 2019 to 2021. The proportion of children and adolescents living with HIV on a DTG-based ART regimen was 41.96% among all CALHIV on ART in Tanzania Mainland. The proportion of viral suppression among CALHIV on DTG based was 91.64%. Furthermore, 66.19% of previously unsuppressed became suppressed and 88.45% of previously suppressed remained suppressed. The proportion of HIV viral suppression on a DTG-based regimen among children and adolescents living with HIV in our study is approximately similar to 91.5% and 92%, which were reported in Nigeria [10] and Ethiopia [8]. Though, it is higher compared to 84.00% and 80.0% which were reported in the USA [11] and Kenya [12]. A possible explanation is the difference in management guidelines of viral suppression across countries that explains variations based on standard copies/ml per country. Among previously unsuppressed patients at baseline, 66.1% achieved viral suppression after shifting to DTG-based regimen and among previously suppressed patients at baseline, 88.4% remained suppressed. This figure is approximately similar to studies reported in Italy, Ireland, and Nigeria [9, 10, 11]. Among ART-naïve participants on DTG-based regimen, viral suppression of 91.7% after six months period. This figure is approximately similar to studies in Uganda and France [12, 13]. In addition, ART naïve participants had a higher proportion of viral suppression (93.2%) compared to ART experienced who shifted to a DTG based regimen with 91.4%. The findings are similar to studies in western India [18], Nigeria [14], and Uganda [16]. It showed a good response to the DTG-based regimen which may reduce the risk of developing viral resistance [19].

This study found several factors independently associated with viral suppression including duration on ART of more than 24 months. Similar findings have been reported elsewhere in the USA [20], France [17], and Kenya [12]. It can be explained by the evidence from clinical practice, which suggested that prolonged ART can reduce viral load below the limit of detection for a long-term period [8].

We also found 'Ever received a multi-month prescription (MMP)' to be significantly related with viral suppression compared to participants who never received a multi month prescription. Participants who ever received multi-month prescriptions are 1.25 more likely to achieve viral suppression compared to those who never received multi-month prescriptions, which is consistent with the findings of studies conducted in Ethiopia [21] and Kenya [22]. It may be the case that those who do not receive this multi-month prescription for viral suppression have poor adherence due to a drop in drug concentration in body fluids because their viral load increases as a result of their inability to suppress HIV replication, which in turn causes their viral load to increase.

In this study, at baseline, we also found the age of children and adolescents living with HIV to have a significant effect on viral suppression. Children and adolescents living with HIV aged 5-14 years were less likely to achieve viral suppression compared to children and adolescents living with HIV aged 1-4 years. The results are consistent with reports from the USA [23] and Zimbabwe [24]. This can be explained by the fact that adolescents and young adults living with HIV experience multiple barriers to adherence including developmental, physical, emotional, behavioural, and social dynamic changes.

Among those previously on ART, a significant association with being previously unsuppressed prior to DTG was associated with being less likely to achieve viral suppression compared to those previously suppressed prior to DTG. Though, those who were ART naïve

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

when starting DTG were more likely to achieve viral suppression compared to those who were previously suppressed prior to DTG, though not statistically significant. The findings are consistent with the study done in nine countries which involved Africa, Asia, North America, and South America [25]. Furthermore, in this study those not retained in care were less likely to achieve viral suppression compared to CALHIV retained in care, which mirrors the findings of the study done in South Africa [26]. This indicates that patients being retained in care were more likely to achieve viral suppression compared to not retained in regular care since adolescents seem to have lower retention rates compared to other age groups. This study utilized the national representative data of children and adolescents living with HIV. Hence, enough statistical power increases the precision of the estimates and makes the findings generalizable to treatment naïve and experienced HIV patients. This is the first in Tanzania to evaluate the HIV viral suppression on a dolutegravir-based regimen and associated factors among children and adolescents living with HIV on ART. Therefore, our study has provided an estimate for viral suppression amongst children and adolescents living with HIV on DTG based regimen and associated factors in Tanzania. This study has a few limitations related to its retrospective nature which utilized secondary data, which might have compromised the data quality and thereby the estimates. This includes missing values in viral load and exposures. The inability to conduct drug resistance testing and antiretroviral drug level testing, which could have helped to determine the contributions of resistance before switching to dolutegravir (DTG) to the risk of treatment failure, especially

among virally unsuppressed children and adolescents living with HIV on ART.

Conclusions

The proportion of viral suppression among children and adolescents living with HIV on dolutegravir (DTG) based regimen in this study was 91.64%. The results encourage widespread use of DTG among eligible CALHIV, especially those in baseline WHO stage I and those who ever received a multi-month prescription, as they were more likely to achieve viral suppression. Viral suppression among CALHIV on DTG was associated with age 5-14, duration on ART more than 24 months, ever received a multi-month prescription, WHO stage I, experienced unsuppressed prior to DTG, not retained in care and living in coastal zone.

Based on the findings from this study, we recommend the following. All children and adolescents living with HIV who are currently receiving other ART (PI or NNRTI) regimens, particularly those who are unsuppressed should switch to a dolutegravir (DTG)-based regimen if eligible. We recommend this because of its strong association in reducing viral load. Dolutegravir based regimen maintains viral suppression but weight gain after its use needs further research to check whether it is beneficial or harmful.

None of the authors has any conflict of interest in the content of this manuscript.

Authors' contributions

AAM contributed to the design of the study, performed the statistical analysis, and drafted the manuscript. MSdB, GM, CA and MJM edited the final draft of the manuscript and approved the final manuscript.

Acknowledgments

Besides my supervisors, I would like to thank all members of the Department of Epidemiology and Applied Biostatistics and National Aids Control Programme (NACP) for their assistance, encouragement, constructive comments, and recommendation. I do extend my sincere gratitude to the National Aids Control Program (NACP) for the permission to access patient level information in the CTC 2 Databases.

List of abbreviations

343

344

ART Antiretroviral Therapy

CALHIV Children and Adolescents Living with HIV

CTC Care and Treatment Clinic

DTG Dolutegravir

HIV Human Immunodeficiency Virus

MMP Multi-month Prescription

NNRTI Non-Nucleoside Reverse Transcript Inhibitor

PI Protease Inhibitor

VS Viral Suppression

WHO World Health Organization.

References

345

- 1. WHO. World Health Organization (WHO) recommends dolutegravir as preferred HIV
- treatment option in all populations [Internet]. 2021 [cited 2022 Jan 10]. Available from:
- 348 https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-
- 349 treatment-option-in-all-populations
- 2. UNAIDS. United Republic of Tanzania, HIV and AIDS estimates [Internet]. 2021 [cited
- 351 2022 Jan 10]. Available from:
- 352 http://www.unaids.org/en/regionscountries/countries/unitedrepublicoftanzania/,
- 353 3. National Bureau of Statistics. Tanzania HIV Impact Survey (THIS) 2016-2017. Tanzania
- 354 HIV Impact Surv 2016-2017 [Internet]. 2018;2016–7. Available from:
- https://phia.icap.columbia.edu/wp-content/uploads/2019/06/FINAL THIS-2016-2017 Final-
- 356 Report 06.21.19 for-web TS.pdf
- 4. MoHCDGEC. Tanzania Health Sector Strategic Plan 2021-2026. Tanzania Heal Sect Strategic Plan 2021-2026.
- 358 Plan 2021-2026. 2021;2026:104.
- 5. Makadzange AT, Higgins-Biddle M, Chimukangara B, Birri R, Gordon M, Mahlanza T, et
- al. Clinical, Virologic, Immunologic outcomes and emerging HIV Drug resistance patterns in
- 361 children and adolescents in public ART Care in Zimbabwe. PLoS One. 2015;10:1–18.
- 6. Bruzzese E, Lo Vecchio A, Smarrazzo A, Tambaro O, Palmiero G, Bonadies G, et al.
- 363 Dolutegravir-based anti-retroviral therapy is effective and safe in HIV-infected paediatric
- patients. Ital J Pediatr. Italian Journal of Pediatrics; 2018;44:1–5.
- 7. Shantanam S. Safety, tolerability and efficacy of generic dolutegravir (DTG) containing
- ART regimen among South Indian HIV-infected patients. Clin Infect Dis. 2018;176:139–48.

- 8. Mehari EA, Muche EA, Gonete KA. Virological suppression and its associated factors of
- dolutegravir based regimen in a resource-limited setting: An observational retrospective study
- in Ethiopia. HIV/AIDS Res Palliat Care. 2021;13:709–17.
- 9. Briand C, Dollfus C, Caseris M, Kantor E, Avettand-fènoël V, Descamps D, et al.
- 371 Dolutegravir Based cART in Vertically-HIV-1-Infected Adolescents in Real-Life Setting. J Int
- 372 AIDS Soc. 2016;812.
- 10. Harcourt P, Paul NI, Ugwu RO. Dolutegravir (DTG) Based Fixed Dose Combination (
- FDC) of Tenofovir / Lamivudine / Dolutegravir (TLD) and Viral Load Suppression in
- 375 Children in. J Sci Res Reports. 2020;26:52–9.
- 11. Rolle CP, Nguyen V, Hinestrosa F, Dejesus E. Virologic outcomes of switching to
- dolutegravir functional mono or dual therapy with a non cytosine nucleoside analog: a
- 378 retrospective study of treatment experienced, patients living with HIV. AIDS Res Ther
- 379 [Internet]. BioMed Central; 2021;18:26. Available from: https://doi.org/10.1186/s12981-021-
- 380 00352-0
- 12. Tsikhutsu I, Bii M, Dear N, Ganesan K, Kasembeli A, Sing'oei V, et al. Prevalence and
- 382 Correlates of Viral Load Suppression and Human Immunodeficiency Virus (HIV) Drug
- 383 Resistance Among Children and Adolescents in South Rift Valley and Kisumu, Kenya. Clin
- 384 Infect Dis. 2022;1–9.
- 13. Carlo D Di, Falasca F, Palermo E, Mezzaroma I, Fimiani C, Siccardi G, et al. Dolutegravir-
- Based Regimen for Maintenance of Viral Suppression in People Living with HIV : 48-Week
- Results in Real-Life Setting. AIDS Res Hum Retroviruses. 2021;37:478–85.
- 388 14. Soriano V, Labarga P, Bisallah CI, Ochigbo M, Muhammad O, Sulaiman B, et al.
- 389 Effectiveness of Dolutegravir (DTG), an HIV integrase inhibitor in improving viral load
- suppression among HIV inf ... IOSR J Dent Med Sci. 2014;19:27–32.

- 15. Wagas S, Connor MO, Levey C, Mallon P, Sheehan G, Patel A, et al. Experience of
- dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital
- 393 in Ireland. SAGE Open Med. 2016;4:1–3.
- 16. Ndashimye E, Arts EJ. International Journal of Infectious Diseases Dolutegravir response
- in antiretroviral therapy naïve and experienced patients with M184V / I: Impact in low-and
- 396 middle-income settings. Int J Infect Dis [Internet]. International Society for Infectious
- 397 Diseases; 2021;105:298–303. Available from: https://doi.org/10.1016/j.ijid.2021.03.018
- 17. Lambert-niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard J, et al. INSTI-Based
- 399 Triple Regimens in Treatment-Naïve HIV- Infected Patients Are Associated With HIV-RNA
- Viral Load Suppression at Ultralow Levels. Open Forum Infect Dis. 2019;1–9.
- 401 18. Patel AK, Patel KK, Pujaril S, Patel JK, Kumar A. Virological outcome and frequency of
- low level viremia in patients receiving generic dolutegravir containing regimen at a large
- 403 tertiary care clinic in Western India. Indian J Sex Transm Dis AIDS. 2021;42:31–7.
- 404 19. Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, et al. MAJOR
- ARTICLE ACTG A5353 : A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment
- of Human Immunodeficiency Virus-1 (HIV-1) infected Participants With HIV-1 RNA < 500
- 407 000 Copies / mL. Clin Infect Dis. 2018;66:1689–97.
- 408 20. Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater Weight
- 409 Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin
- 410 Infect Dis. 2020;70:1267–74.
- 21. Singh R, Mukherjee A, Singla M, Das BK, Kabra SK, Lodha R. Immunological and
- Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children.
- Indian J Pediatr. The Indian Journal of Pediatrics; 2017;84:893–6.

- 414 22. Humphrey JM, Genberg BL, Keter A, Musick B, Gardner A, Hogan JW, et al. Viral
- suppression among children and their caregivers living with HIV in western Kenya. J Int AIDS
- 416 Soc. 2019;22:1–10.
- 23. Levy ME, Griffith C, Ellenberger N, Monroe AK, Castel AD, Rakhmanina N. Outcomes
- 418 of Integrase Inhibitor-Based Antiretroviral Therapy in a Clinical Cohort of Treatment-
- Experienced Children, Adolescents, and Young Adults with HIV Infection. Physiol Behav.
- 420 2017;176:139–48.
- 421 24. Id TA, Takarinda KC, Phillips A, Ndhlovu C. Provision of HIV viral load testing services
- in Zimbabwe: Secondary data analyses using data from health facilities using the electronic
- Patient Monitoring System. PLoS One [Internet]. 2021;16:1–18. Available from:
- 424 http://dx.doi.org/10.1371/journal.pone.0245720
- 25. Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montañez N, et al. Pharmacokinetics,
- safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and
- children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1 2 trial. 2022;9.
- 428 26. Ahmed B, Elashi Y. Determinants of viral suppression among adolescents on antiretroviral
- 429 therapy in Thabo Mofutsanyane District Municipality, Free State province, South Africa.
- 430 African J AIDS Res. 2021;37.